vs
碧迪（BDX）与特灵科技（TT）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是特灵科技的1.0倍（$5.3B vs $5.1B），特灵科技净利率更高（11.5% vs 7.3%，领先4.2%），特灵科技同比增速更快（5.5% vs -0.4%），过去两年特灵科技的营收复合增速更高（10.5% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
特灵科技是一家注册地位于爱尔兰的企业，核心业务覆盖采暖、通风、空调及制冷系统领域。品牌历史可追溯至150多年前，历经多次并购与分拆：2008年暖通空调厂商特灵被美国工业工具制造商英格索兰收购，2020年工具业务分拆独立为英格索兰，剩余业务正式更名特灵科技。
BDX vs TT — 直观对比
营收规模更大
BDX
是对方的1.0倍
$5.1B
营收增速更快
TT
高出5.9%
-0.4%
净利率更高
TT
高出4.2%
7.3%
两年增速更快
TT
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $5.1B |
| 净利润 | $382.0M | $591.3M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 15.9% |
| 净利率 | 7.3% | 11.5% |
| 营收同比 | -0.4% | 5.5% |
| 净利润同比 | 24.0% | -2.2% |
| 每股收益（稀释后） | $1.34 | $2.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXTT
| Q4 25 | $5.3B | $5.1B | ||
| Q3 25 | $5.9B | $5.7B | ||
| Q2 25 | $5.5B | $5.7B | ||
| Q1 25 | $5.3B | $4.7B | ||
| Q4 24 | $5.2B | $4.9B | ||
| Q3 24 | $5.4B | $5.4B | ||
| Q2 24 | $5.0B | $5.3B | ||
| Q1 24 | $5.0B | $4.2B |
净利润BDXTT
| Q4 25 | $382.0M | $591.3M | ||
| Q3 25 | $493.0M | $847.6M | ||
| Q2 25 | $574.0M | $874.8M | ||
| Q1 25 | $308.0M | $604.9M | ||
| Q4 24 | $303.0M | $604.3M | ||
| Q3 24 | $400.0M | $772.0M | ||
| Q2 24 | $487.0M | $755.3M | ||
| Q1 24 | $537.0M | $436.3M |
毛利率BDXTT
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | 36.9% | ||
| Q2 25 | 47.8% | 37.6% | ||
| Q1 25 | 42.8% | 35.8% | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | 36.3% | ||
| Q2 24 | 46.2% | 36.5% | ||
| Q1 24 | 45.7% | 34.6% |
营业利润率BDXTT
| Q4 25 | 10.5% | 15.9% | ||
| Q3 25 | 11.8% | 20.3% | ||
| Q2 25 | 16.0% | 20.3% | ||
| Q1 25 | 10.4% | 17.5% | ||
| Q4 24 | 8.8% | 16.6% | ||
| Q3 24 | 11.4% | 18.8% | ||
| Q2 24 | 12.1% | 19.5% | ||
| Q1 24 | 14.5% | 15.0% |
净利率BDXTT
| Q4 25 | 7.3% | 11.5% | ||
| Q3 25 | 8.4% | 14.8% | ||
| Q2 25 | 10.4% | 15.2% | ||
| Q1 25 | 5.8% | 12.9% | ||
| Q4 24 | 5.9% | 12.4% | ||
| Q3 24 | 7.4% | 14.2% | ||
| Q2 24 | 9.8% | 14.2% | ||
| Q1 24 | 10.6% | 10.3% |
每股收益（稀释后）BDXTT
| Q4 25 | $1.34 | $2.64 | ||
| Q3 25 | $1.71 | $3.78 | ||
| Q2 25 | $2.00 | $3.89 | ||
| Q1 25 | $1.07 | $2.67 | ||
| Q4 24 | $1.04 | $2.65 | ||
| Q3 24 | $1.37 | $3.39 | ||
| Q2 24 | $1.68 | $3.30 | ||
| Q1 24 | $1.85 | $1.90 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $1.8B |
| 总债务越低越好 | — | $4.6B |
| 股东权益账面价值 | $25.3B | $8.6B |
| 总资产 | $54.8B | $21.4B |
| 负债/权益比越低杠杆越低 | — | 0.54× |
8季度趋势，按日历期对齐
现金及短期投资BDXTT
| Q4 25 | $740.0M | $1.8B | ||
| Q3 25 | $641.0M | — | ||
| Q2 25 | $735.0M | — | ||
| Q1 25 | $667.0M | — | ||
| Q4 24 | $711.0M | $1.6B | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $2.3B | — |
总债务BDXTT
| Q4 25 | — | $4.6B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BDXTT
| Q4 25 | $25.3B | $8.6B | ||
| Q3 25 | $25.4B | $8.3B | ||
| Q2 25 | $25.5B | $7.8B | ||
| Q1 25 | $25.2B | $7.5B | ||
| Q4 24 | $25.2B | $7.5B | ||
| Q3 24 | $25.9B | $7.6B | ||
| Q2 24 | $25.9B | $6.9B | ||
| Q1 24 | $25.6B | $6.9B |
总资产BDXTT
| Q4 25 | $54.8B | $21.4B | ||
| Q3 25 | $55.3B | $21.4B | ||
| Q2 25 | $54.9B | $21.0B | ||
| Q1 25 | $54.5B | $20.1B | ||
| Q4 24 | $54.7B | $20.1B | ||
| Q3 24 | $57.3B | $20.9B | ||
| Q2 24 | $55.6B | $20.2B | ||
| Q1 24 | $54.2B | $19.3B |
负债/权益比BDXTT
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.64× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $1.2B |
| 自由现金流经营现金流 - 资本支出 | $549.0M | — |
| 自由现金流率自由现金流/营收 | 10.5% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 1.72× | 1.96× |
| 过去12个月自由现金流最近4个季度 | $2.6B | — |
8季度趋势，按日历期对齐
经营现金流BDXTT
| Q4 25 | $657.0M | $1.2B | ||
| Q3 25 | $1.4B | $1.0B | ||
| Q2 25 | $1.2B | $692.1M | ||
| Q1 25 | $164.0M | $339.5M | ||
| Q4 24 | $693.0M | $899.9M | ||
| Q3 24 | $1.2B | $1.3B | ||
| Q2 24 | $1.3B | $695.9M | ||
| Q1 24 | $514.0M | $247.2M |
自由现金流BDXTT
| Q4 25 | $549.0M | — | ||
| Q3 25 | $1.0B | $935.6M | ||
| Q2 25 | $1.0B | $602.2M | ||
| Q1 25 | $35.0M | $220.6M | ||
| Q4 24 | $588.0M | $774.3M | ||
| Q3 24 | $882.0M | $1.2B | ||
| Q2 24 | $1.1B | $623.0M | ||
| Q1 24 | $380.0M | $163.4M |
自由现金流率BDXTT
| Q4 25 | 10.5% | — | ||
| Q3 25 | 17.0% | 16.3% | ||
| Q2 25 | 19.0% | 10.5% | ||
| Q1 25 | 0.7% | 4.7% | ||
| Q4 24 | 11.4% | 15.9% | ||
| Q3 24 | 16.2% | 22.3% | ||
| Q2 24 | 22.4% | 11.7% | ||
| Q1 24 | 7.5% | 3.9% |
资本支出强度BDXTT
| Q4 25 | 2.1% | — | ||
| Q3 25 | 6.0% | 1.2% | ||
| Q2 25 | 3.2% | 1.6% | ||
| Q1 25 | 2.4% | 2.5% | ||
| Q4 24 | 2.0% | 2.6% | ||
| Q3 24 | 5.4% | 1.6% | ||
| Q2 24 | 3.6% | 1.4% | ||
| Q1 24 | 2.7% | 2.0% |
现金转化率BDXTT
| Q4 25 | 1.72× | 1.96× | ||
| Q3 25 | 2.75× | 1.18× | ||
| Q2 25 | 2.12× | 0.79× | ||
| Q1 25 | 0.53× | 0.56× | ||
| Q4 24 | 2.29× | 1.49× | ||
| Q3 24 | 2.94× | 1.69× | ||
| Q2 24 | 2.66× | 0.92× | ||
| Q1 24 | 0.96× | 0.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
TT
| Services | $2.8B | 55% |
| Other | $2.3B | 45% |
